X @The Wall Street Journal

Healthcare giant Johnson & Johnson reported nearly 10% revenue growth for the latest quarter on strong cancer drug sales that offset a steep decline from one of its best-selling drugs, Stelara https://t.co/XLsm0a9nZS ...